PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS

摘要

The present disclosure provides compounds of Formula (IA) and or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.;

主权项

1. A compound of Formula (IA):where:
—Z— is:and
Rc is: (a) —C(CH3)2-(4-R4-piperazin-1-yl) where R4 is hydrogen, alkyl, alkoxyalkyl, haloalkyl, alkylsulfonyl, alkoxycarbonyl, acyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl; (b) —C(CH3)2-(3-oxo-4-Ra-piperazin-1-yl) where Ra is hydrogen, alkyl, cycloalkyl, alkoxyalkyl, haloalkyl, or oxetan-3-yl and the piperazinyl ring is additionally optionally substituted with one or two alkyl; (c) —C(CH3)2—NRboxetan-3-yl where Rb is hydrogen, alkyl, alkoxyalkyl, or cycloalkyl; (d) —C(CH3)2—Rc where Rc iswhere one or two of X1, X2 and X3 are nitrogen and the rest are carbon and the ring is optionally substituted with one or two substituents independently selected from alkyl, haloalkyl, or halo; or
(e) —C(CH3)2-2-oxa-6-azaspiro[3.3]heptan-6-yl, or —C(CH3)2—CH2morpholine-4-yl; or
and/or a pharmaceutically acceptable salt thereof.